News from the Bench
Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.
Important Ordering DetailsCustom Ordering Details: Sections are cut freshly upon ordering. Please allow up to three business days for your product to be processed.
CST Antibody Performance Guarantee
To Purchase # 8103S
|8103S||1 Pack (5 slides)||$132.00.0|
Find answers on our FAQs page.
- Additional protein information
- Analytical tools
SignalSlide® Phospho-p44/42 MAPK (Thr202/Tyr204) IHC Controls #8103
Immunohistochemical analysis of paraffin-embedded NIH/3T3 cells, treated with U0126 #9903 (left) or TPA #4174 (right), using Phospho-p44/42MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370.Learn more about how we get our images
Gallery: SignalSlide® Phospho-p44/42 MAPK (Thr202/Tyr204) IHC Controls #8103
- Immunohistochemical analysis of paraffin-embedded NIH/3T3 cells, treated with U0126 #9903 (left) or TPA #4174 (right), using Phospho-p44/42MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370.
Each control slide contains formalin fixed, paraffin-embedded NIH/3T3 cells, treated with either U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene) #9903 or TPA (12-O-Tetradecanoylphorbol-13-Acetate) #4174 , that serve as a control for phospho-p44/42 MAPK (Thr202/Tyr204) immunostaining. U0126 has been shown to be a highly selective inhibitor of MEK1 and MEK2. TPA induces phosphorylation of p44/42 MAPK. Western blot analysis was performed on extracts derived from the same cells to verify the efficacy of the U0126 and TPA treatments.
To be used with antibodies: 4370, 4376, 4695, 4696, 9102, 9108.
Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059.
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. SignalSlide is a registered trademark of Cell Signaling Technology, Inc.